FDA ends Teva Plan B OTC dominance

Share this article:

Plan B is now going generic. NPR reports that the FDA did a 180 on its July 2012 marketing decision that allowed the emergency contraception to be sold over the counter without an age restriction.

The age-free availability came after legal wrangling that brought together the FDA, the Department of Justice, and the United States District Court for the Eastern District of New York.

Pro-limit parties, which included the Department of Justice and the White House, backed off, keeping it out of the Supreme Court. The détente came with a provision in which the FDA granted drugmaker Teva three years of generic protection. NPR reports that the regulator has changed its mind as long as generic labels note that the drug is meant for women 17 or older.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies